Skip to main content
Have a personal or library account? Click to login
The influence of genetic variability in IL1B and MIR146A on the risk of pleural plaques and malignant mesothelioma Cover

The influence of genetic variability in IL1B and MIR146A on the risk of pleural plaques and malignant mesothelioma

Open Access
|Oct 2020

Figures & Tables

Table 1

Characteristics of subjects included in the study

CharacteristicsControl group
N = 175
Pleural plaques
N = 394
Malignant mesothelioma
N = 277
Testp
GenderMale, N (%)119 (68.0)271 (68.8)202 (72.9)1.757a0.410
Female, N (%)56 (32.0)123 (31.3)75 (27.1)
AgeMedian (25%–75%)55.3 (48.6–63.7)54.9 (48.8–62.7)66.0 (59.0–73.0)151.666b< 0.001
Low, N (%)134 (76.6)278 (71.6) [6]43 (48.3) [188]26.891a< 0.001
Asbestos exposureMedium, N (%)13 (7.4)41 (10.6)24 (27.0)
High, N (%)28 (16.0)69 (17.8)22 (24.7)
SmokingNo, N (%)94 (53.7)194 (49.4) [1]150 (55.6) [7]2.640a0.267
Yes, N (%)81 (46.3)199 (50.6)120 (44.4)

number of missing data is presented in [] brackets

a calculated using Fisher exact test

b calculated using Kruskal-Wallis test

a calculated using Fisher exact test

a calculated using Fisher exact test

Table 2

Association between selected polymorphisms and the risk of developing malignant mesothelioma

SNPGenotypeControls
N (%)
MM
N (%)
OR (95% CI)pOR (95% CI)adj1padj1OR (95% CI)adj2padj2
IL1B rs1143623GG88 (50.3)152 (54.9)referencereference
GC67 (38.3)97 (35.0)0.84 (0.56–1.26)0.3960.82 (0.52–1.29)0.3880.56 (0.29–1.05)0.072
CC20 (11.4)28 (10.1)0.81 (0.43–1.52)0.5140.69 (0.35–1.38)0.2940.34 (0.11–1.04)0.060
GC+CC87 (49.7)125 (45.1)0.83 (0.57–1.22)0.3410.79 (0.52–1.20)0.2660.50 (0.28–0.92)0.025
IL1B rs16944TT21 (12.0)36 (13.0)1.10 (0.60–2.02)0.7560.94 (0.48–1.82)0.8490.53 (0.20–1.43)0.210
TC75 (42.9)118 (42.6)1.01 (0.67–1.51)0.9600.98 (0.63–1.52)0.9110.67 (0.36–1.24)0.198
CC79 (45.1)123 (44.4)referencereference
TC+TT96 (54.9)154 (55.6)1.03 (0.70–1.51)0.8780.97 (0.64–1.47)0.8730.63 (0.35–1.13)0.122
IL1B rs1071676GG105 (60.0)165 (59.6)referencereference
GC60 (34.3)98 (35.4)1.04 (0.69–1.56)0.8510.97 (0.62–1.51)0.8951.00 (0.53–1.89)0.993
CC10 (5.7)14 (5.1)0.89 (0.38–2.08)0.7890.96 (0.38–2.41)0.9312.03 (0.70–5.90)0.194
GC+CC70 (40.0)112 (40.4)1.02 (0.69–1.50)0.9270.97 (0.64–1.48)0.8851.15 (0.64–2.08)0.632
MIR146A rs2910164GG94 (53.7)158 (57.0)referencereference
GC64 (36.6)110 (39.7)1.02 (0.69–1.53)0.9130.91 (0.59–1.41)0.6720.67 (0.36–1.25)0.209
CC17 (9.7)9 (3.2)0.31 (0.13–0.73)0.0080.34 (0.14–0.85)0.0200.39 (0.11–1.38)0.144
GC+CC81 (46.3)119 (43.0)0.87 (0.60–1.28)0.4880.79 (0.52–1.21)0.2780.62 (0.34–1.11)0.109

[i] adj1 = adjustment for age and gender; adj2 = adjustment for age, gender and asbestos exposure; CI = confidence interval; MM = malignant mesothelioma; OR = odds ratio; SNP = single nucleotide polymorphism

Table 3

Association between selected polymorphisms and the risk of developing malignant mesothelioma compared to pleural plaques

SNPGenotypePleural plaques
N (%)
MM
N (%)
OR (95 % CI)pOR (95 % CI)adj1padj1OR (95 % CI)adj2padj2
IL1B rs1143623GG205 (52.0)152 (54.9)referencereference
GC157 (39.8)97 (35.0)0.83 (0.60–1.16)0.2770.88 (0.61–1.27)0.4990.67 (0.39–1.15)0.151
CC32 (8.1)28 (10.1)1.18 (0.68–2.04)0.5541.07 (0.58–1.99)0.8270.65 (0.22–1.86)0.418
GC+CC189 (48.0)125 (45.1)0.89 (0.66–1.21)0.4670.92 (0.65–1.29)0.6170.67 (0.40–1.11)0.123
IL1B rs16944TT50 (12.7)36 (13.0)1.02 (0.63–1.67)0.9230.96 (0.56–1.67)0.8970.54 (0.22–1.34)0.184
TC169 (42.9)118 (42.6)0.99 (0.71–1.38)0.9690.98 (0.68–1.42)0.9290.70 (0.41–1.19)0.186
CC175 (44.4)123 (44.4)referencereference
TC+TT219 (55.6)154 (55.6)1.00 (0.73–1.36)0.9980.98 (0.69–1.38)0.9050.66 (0.40–1.10)0.110
IL1B rs1071676GG233 (59.1)165 (59.6)referencereference
GC145 (36.8)98 (35.4)0.95 (0.69–1.32)0.7780.93 (0.65–1.34)0.7080.92 (0.53–1.60)0.774
CC16 (4.1)14 (5.1)1.24 (0.59–2.60)0.5781.29 (0.56–2.97)0.5532.83 (1.04–7.71)0.042
GC+CC161 (40.9)112 (40.4)0.98 (0.72–1.34)0.9110.97 (0.68–1.37)0.8491.09 (0.66–1.82)0.731
MIR146A rs2910164GG196 (49.7)158 (57.0)referencereference
GC163 (41.4)110 (39.7)0.84 (0.61–1.15)0.2760.84 (0.58–1.20)0.3260.65 (0.38–1.11)0.118
CC35 (8.9)9 (3.2)0.32 (0.15–0.68)0.0030.33 (0.15–0.75)0.0080.34 (0.11–1.09)0.069
GC+CC198 (50.3)119 (43.0)0.75 (0.55–1.02)0.0630.74 (0.53–1.05)0.0920.59 (0.36–0.99)0.046

[i] adj1 = adjustment for age and gender; adj2 = adjustment for age, gender and asbestos exposure; CI = confidence interval; MM = malignant mesothelioma; OR = odds ratio; SNP = single nucleotide polymorphism

DOI: https://doi.org/10.2478/raon-2020-0057 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 429 - 436
Submitted on: Jul 7, 2020
Accepted on: Aug 6, 2020
Published on: Oct 21, 2020
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 Petra Piber, Neza Vavpetic, Katja Goricar, Vita Dolzan, Viljem Kovac, Alenka Franko, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.